Gilead Sciences, Inc. vs Amneal Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown

Gilead Sciences vs. Amneal Pharmaceuticals: A Decade of Gross Profit Trends

In the competitive landscape of pharmaceuticals, Gilead Sciences, Inc. and Amneal Pharmaceuticals, Inc. have showcased distinct financial trajectories over the past decade. From 2014 to 2023, Gilead Sciences consistently outperformed Amneal in terms of gross profit, with figures peaking in 2015 at approximately $28.6 billion. However, a notable decline followed, with profits dropping by around 28% by 2018. Despite this, Gilead maintained a robust average gross profit of $21.6 billion annually.

Conversely, Amneal Pharmaceuticals demonstrated a steady growth pattern, with gross profits increasing by about 82% from 2014 to 2023. This growth trajectory highlights Amneal's strategic advancements in the market, culminating in a gross profit of approximately $820 million in 2023. This comparison underscores the dynamic nature of the pharmaceutical industry, where strategic decisions and market conditions significantly impact financial outcomes.